Researchers generated the ADC by conjugating HzMUC1 with MMAE, and examined the efficacy of HzMUC1-MMAE against the MUC1-positive pancreatic cancer in vitro and in vivo. This evidence concerns the gene MUC1 and pancreatic neoplasm.